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Abstract  
 
Phage display technique has been increasingly researched for vaccine design and delivery strategies in 
recent years. In this study, the AE37 (Ii-Key/HER-2/neu 776–790) peptide derived from HER2 (human 
epidermal growth factor receptor protein) was used as a fused peptide to the lambda phage (λF7) coat 
protein gpD, and the phage nanoparticles were used to induce antitumor immunogenicity in a TUBO 
model of breast cancer in mice. Mice were immunized with the AE37 peptide displaying phage, λF7 
(gpD::AE37) every 2-week intervals over 6-weeks, then the generated immune responses were 
evaluated. An induction of CTL immune response by the λF7 (gpD::AE37) construct compared to the 
control λF7 and buffer groups was observed in vitro. Moreover, in the in vivo studies, the vaccine 
candidate showed promising prophylactic and therapeutic effects against the HER2 overexpressing 
cancer in BALB/c mice.  
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Abstract  46 
 47 
Phage display technique has been increasingly researched for vaccine design and delivery 48 
strategies in recent years. In this study, the AE37 (Ii-Key/HER-2/neu 776–790) peptide derived 49 
from HER2 (human epidermal growth factor receptor protein) was used as a fused peptide to the 50 
lambda phage (λF7) coat protein gpD, and the phage nanoparticles were used to induce antitumor 51 
immunogenicity in a TUBO model of breast cancer in mice. Mice were immunized with the 52 
AE37 peptide displaying phage, λF7 (gpD::AE37) every 2-week intervals over 6-weeks, then the 53 
generated immune responses were evaluated. An induction of CTL immune response by the λF7 54 
(gpD::AE37) construct compared to the control λF7 and buffer groups was observed in vitro. 55 
Moreover, in the in vivo studies, the vaccine candidate showed promising prophylactic and 56 
therapeutic effects against the HER2 overexpressing cancer in BALB/c mice.  57 
 58 
Keywords: Antitumor Immunogenicity; HER2/neu; Becteriophage λF7; AE37; vaccine; Breast 59 
cancer 60 
 61 
 62 
1. Introduction 63 
  64 
Cancer vaccination is a type of immunotherapy in which tumor antigens are presented to the 65 
patient's own immune system, via variety of delivery systems, in order to prime/boost an 66 
immune response. Several anticancer studies based on phage display technology have been 67 
reported [1, 2]. In cancer vaccination, a specific cellular immune response is induced and 68 
translated to antitumor activity, delaying tumor growth and resulting in improved survival. Such 69 
vaccines may also be used in prophylaxis and therapy of cancers [3, 4]. Peptide-based cancer 70 
vaccines are currently under intensive research and research in the field is considered a hot topic 71 
exploited by several clinical research protocols. Peptide vaccines designed to combat cancer  72 
mechanistically generate a T-cell immune response against tumor in the host [5].  73 
The human epidermal growth factor receptor 2 (HER2) has an intracellular domain with tyrosine 74 
kinase activity and is normally expressed during fetal development. The HER2 gene is located on 75 
chromosome 17q21 and encodes for a 185-kD transmembrane glycoprotein receptor [6]. 76 
Receptor activation by dimerization of its extracellular domain mediates proliferation signaling 77 
including PI3K/Akt or MAP kinase pathways, enhancing cell growth, division and survival. This 78 
protein is involved both in oncogenesis and tumor survival. Some specific sequences of HER2 79 
are adequately immunogenic which can stimulate cytotoxic T lymphocytes (CTLs). This 80 
instructs the cells to recognize and kill cancer cells expressing HER2/neu in vitro.  81 
The novel peptide sequence AE37 is a Ii-Key hybrid of the AE36 (HER2776-790) derived from the 82 
intracellular domain of HER2. It is an MHC class II hybrid molecule, potent to stimulate 83 
peptide-specific CD4+ and CD8+ T cells. AE37 is composed of the sequence: Ac-84 
LRMKGVGSPYVSRLLGICL-NH2. This particular peptide sequence of HER2 is 100 % 85 
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identical in human, mouse and rat [7-9]. It is safe and is well tolerated as a vaccine. Published 86 
reports on its immunological monitoring in human has shown that this immunogenic peptide 87 
caused specific long term immunity in most of the evaluated patients [10, 11].  88 
Phage display describes a technique used in biotechnology in which a peptide or protein of 89 
interest is genetically fused to a coat protein of a bacteriophage, resulting in the display of the 90 
protein fusion on the surface of the phage particle. The DNA encoding the peptide-coat protein 91 
fusion may reside in an expression vector expressed in the bacterial host and added to the phage 92 
pro-head by genetic complementation [1, 12]. Among its other uses, the phage display technique 93 
can also be used to design vaccine adjuvant /delivery systems where an antigenic amino acid 94 
sequence can be expressed as a peptide on the phage head [13].  95 
Phages have been used as adjuvant-like particles. Compared to standard vaccination,  a 96 
vaccination practice using phage particles, requires lower doses of immunogenic molecules but 97 
produces higher immunogenicity responses [14, 15]. Hybrid phage vaccines induce effective 98 
humoral and cellular responses. In addition to displaying the antigenic molecules, phages may be 99 
used as targeting molecules providing significant advantages for application in targeted therapy 100 
[16, 17]. Phage vaccines have fundamental properties of the phage nanoparticles including high 101 
stability in a broad range of pH and low cost of phage design and production. Moreover, phage 102 
nanoparticles cannot proliferate in eukaryotic cells and have minimal side effects in the 103 
mammalian host [18]. 104 
Bacteriophage lambda (λ) among its other applications, has been used to display immunologic 105 
peptides (1). The lytic nature of λ and the conformation of its major capsid protein (gpD) offer 106 
several advantages as a phage display candidate. The unique form of the λ capsid and the 107 
potential to exploit gpD in design of controlled phage decoration will benefit applications of λ 108 
display [19]. The capsid protein gpD, which is necessary for phage viability, has been used 109 
extensively for fusion of polypeptides in phage display technique. The DNA sequence 110 
representing the capsid-linker-polypeptide can be cloned and expressed from a plasmid in 111 
Escherichia coli. This protein expressed by the plasmid could be received by λDam15 phage 112 
particles infecting the cloned bacteria. λF7 bacteriophage (λimm21Dam15) has a mutation 113 
(Dam15) in the gpD gene where glutamine is replaced with a stop codon TAG resulting in a 114 
truncated gpD fragment. Thus, the translation of λF7 in a non-suppressor or a wild-type E. coli 115 
results in unassembled and nonviable phage in the absence of complementing gpD from a 116 
plasmid. A functional, wild-type length,  gpD protein can be produced with the activity of an 117 
amber suppressor strain of E. coli, which has the tRNA capability to recognize the stop codon as 118 
a specific amino acid [12]. 
 
119 
In the current study, an amber suppressor strain of E. coli (W3101 SupE) was used for cloning of 120 
an expression plasmid containing the gpD capsid-linker-polypeptide (AE37) gene. This strain 121 
has the capability to insert glutamine in place of the amber stop codon, producing wild-type gpD. 122 
The cloned plasmid used had an ampicillin resistance gene, to avoid proliferation of undesirable 123 
strains on medium and for the selction of plasmid containing strains. λF7 could receive the gpD-124 
linker-antigenic polypeptide (AE37) from this plasmid by infecting the amber suppressor strain 125 
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(SupE) and therefore surface decorated with AE37 linked to the gpD protein by a linker. We 126 
decided to investigate the in vitro and in vivo immunity induction of the AE37 displaying λ 127 
phage nanoparticles in a TUBO breast cancer model of BALB/c mice. 128 
 129 
 130 
2. Materials and methods 131 
2.1 Bacterial strains, phages and plasmids 132 
 133 
Bacterial strains, phages and plasmids used in this study are listed in Table 1. For general 134 
purpose phage plating and titration, Escherichia coli strain BB4 (supF58 supE44) was used.  135 
Plasmid pGPD::AE37 was constructed using plasmid pPL451-gpD. The procedure was based on 136 
the protocols reported in previous studies [12, 20]. To produce the fusion peptide, the terminal 137 
stop codon from gpD was removed and an in-frame fusion with the AE37 sequence was created.  138 
The two fragments were separated by an in-frame short linker encoding 17 amino acids 139 
(ACTAGCGGGTTCTGGTTCCGGTTCTGGTTCCGGTTCTGGC) that was placed between 140 
and followed by a KpnI cut site to maximize fusion functionality and also allow for additional 141 
fusions to be designed in the future. The gpD-linker-AE37 sequence was then amplified and 142 
cloned into the HpaI and NcoI sites on pGPD, placing it under the control of the PL strong 143 
promoter that is regulated by the temperature-inducible λ repressor CI857 that confers 144 
temperature-regulated expression [21]. 145 
 146 
 147 
2.2 Phage lysate preparation 148 
 149 
Cultures of transformed E. coli strain (SupE) (pGPD::AE37) were grown on LB agar plates with 150 
ampicillin and incubated overnight at 37 °C. Dilutions of primary lysates (1:1000) were prepared 151 
in 100 µL of TN buffer (0.01 M Tris–HCl and 0.1 M NaCl, pH 7.8), (Fisher Scientific, USA). 152 
Lysate dilutions were added to 500 µL of cells (1x108 CFU/mL), incubated for 2 hours at 153 
experimental room temperature prior to adding 5 ml of top LB agar (LB broth + 0.7 % agar, 154 
Bacto Agar from Difco Laboratories, Sparks, MD). The plates were then incubated overnight at 155 
37 °C. Plate lysates were prepared by adding 10 mL of ice cold sterile TN buffer to the surface of 156 
the plate, incubating overnight at 4 °C. The top agar was scratched by a sterile loop and the 157 
resulting solution with the loosened top agar were then transferred aseptically to a conical tube, 158 
mixing and centrifuging at 8000 RPM (Hettich, Germany) for 20 min at 4 °C. The resulting 159 
supernatant was then poured in a fresh ice-cold conical tube and 2 µL of chloroform was added 160 
to kill the remaining host bacteria. Lysates were then precipitated by centrifuging at 8000 RPM 161 
for 10 min at 4 °C.  The supernatant was removed and transferred into a new sterile tube.  Then 1 162 
µL DNase (Sina Colon, IRAN) was added to the lysate to remove any remaining free DNA in 163 
the lysate. The lysates were then passed through a 0.45 µm filter and kept at 4 o C until use.  164 
 165 
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 166 
 167 
2.4 Phage purification 168 
 169 
Polyethylene glycol (PEG)-8000 (Fisher Scientific, USA) was added to a final concentration of 170 
10 % (w/v). The bacteriophage particles were then recovered by centrifugation at 8000 RPM for 171 
10 min at 4 °C. The supernatant was discarded and 1 ml TN buffer was added to the pellet and 172 
kept overnight at 4 °C. To separate PEG and cell debris from the phage nanoparticles, an equal 173 
volume of chloroform was added. The mixture was mixed gently for 30 seconds and spun at 174 
4300 RPM for 15 min at 4 °C. The aqueous phase, which contained the bacteriophage particles, 175 
was then removed. The solution was filtered through a sterile 0.45 µm syringe filter (BD 176 
Discardit, India). To remove endotoxin (LPS), 1% Triton X-114 was added and the solution was 177 
incubated in a shaker incubator for 30 min at 4 °C (Innova 4080 Incubator Shaker). Then the 178 
solution was incubated at 37 °C for 10 min before centrifugation at 14000 RPM for 10 min at 25 179 
°C. In order to maximize endotoxin elimination, the phage purification procedure was repeated 180 
three times. The phage solutions were tittered at each step of purification by standard viability 181 
assays on fresh Sup+ BB4 (supE, supF) E. coli cells as these cells have been reported to 182 
consistently produce the highest titers of λF7 [19]. For endotoxin content evaluation, the samples 183 
were analyzed by a standard Limulus Amebocyte Lysate (LAL) assay (Samen Research Institute, 184 
Samen Pharmaceutical Co. Mashhad, Iran). Samples were kept at 4 °C until use.    185 
 186 
 187 
2.5 Animals and cell lines 188 
 189 
Female BALB/c mice (four to six weeks old) were purchased from Pasteur Institute (Tehran, 190 
Iran). All the protocols were approved by the Ethical and Research Advisory Committee, 191 
Mashhad University of Medical Sciences (MUMS), according to animal welfare guidelines 192 
(Project code:  MUMS 922610). 193 
TUBO cell line which overexpresses the rat HER2/neu protein (rHER2) was kindly provided by 194 
Dr. Pier-Luigi Lollini (Department of Clinical and Biological Sciences, University of Turin, 195 
Orbassano, Italy) and was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) with 20 % 196 
fetal bovine serum (FBS). A murine colon carcinoma cell line, CT26, which does not express 197 
HER2 was purchased from Pasteur Institute (Tehran, Iran) and cultured in RPMI-1640 medium 198 
supplemented with 10 % FBS and served as a negative control. 199 
 200 
2.6 Immunization of BALB/c mice 201 
 202 
The immunization procedure was performed for three times at two week intervals. BALB/c mice 203 
were divided into three experimental groups (10 mice in each group). The mice in the test group 204 
were injected with 100 µL of 108 (PFU/mL) AE37 displaying phage nanoparticles [λF7 205 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
(gpD::AE37)] subcutaneously (SC). For control groups, either 100 µL of 108 (PFU/mL) λF7 or 206 
100 µL TN buffer was injected (SC).  207 
 208 
2.7 Analysis of T-Cell immune responses (the extracellular cytokine assay) 209 
  210 
ELISA assay was performed using anti mouse IF-γ and anti-mouse IL-4 ELISA kits.  According 211 
to the manufacturer’s instruction one day before the test, two ELISA 96-well plates were coated 212 
with mouse anti-IL-4 and anti-IFN-γ antibodies. Plates were incubated at 4º C overnight. Serum 213 
and splenocytes of the mice (three mice from each group) were collected for evaluation the 214 
amounts of IL-4 and IFN-γ according to the instruction (eBioscience, San Diego, CA, USA). All 215 
assays were performed in triplicate. Phytohaemagglutinin (PHA) was used for stimulation 216 
production of cytokine as positive control.  217 
 218 
2.8 In vitro CTL assay 219 
 220 
Two weeks after the final vaccination, mice were sacrificed and splenocytes harvested by 221 
ammonium chloride lysis buffer (NH4Cl, 0.1 M and Tris, 0.2 M). Viable splenocytes were 222 
counted using trypan blue (0.4 %, w/v) and re-stimulation was performed with the 108 PFU 223 
AE37 displaying phages (100 µL). TUBO cells (target cells) were incubated with 12.5 µM 224 
Calceine AM (Calcein-AM, Invitrogen, USA) at 37 °C for one hour in the dark [22]. Triton X-225 
100 (2 %) and culture medium were added to the maximum and minimum release wells 226 
respectively. Fluorescence intensity was measured at 485 nm (excitation) and of 538 nm 227 
(emission) using a fluorescent plate reader (FLX 800, BioTek Instruments Inc. USA). The 228 
percentage of specific lysis was calculated by the following formula: (release by CTLs - 229 
minimum release by targets)/ (maximum release by targets - minimum release by targets) × 100 230 
[23, 24]. To show the specificity of cytotoxic activity, non-expressing rHER2/neu, CT26 cells 231 
were used as negative controls.  232 
 233 
2.9 Prophylactic Model of TUBO Challenge 234 
 235 
Fourteen days after the last vaccination, 5×105 TUBO cells in 50 µL PBS buffer were injected 236 
SC in the right flank of immunized mice (seven mice per group). Mice were monitored every 237 
day. Three orthogonal diameters of the developing tumor (a, b, c) were measured with a digital 238 
caliper. The tumor volumes were calculated according to the formulation [(height × width × 239 
length) × 0.5]. The equation of the line obtained by exponential regression of the tumor growth 240 
curve was used for TTE (time to reach the end point) and based on the difference between the 241 
median TTE of treatment group (T) and the median TTE of the control group (C) were used to 242 
calculate the percent TGD (the percent of tumor growth delay) (TGD % = [(T- C) /C] × 100]) for 243 
each mouse. For ethical reasons, mice were sacrificed if the following conditions observed: the 244 
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tumor volume was greater than 1000 mm3, the body weight loss was over 15 % of initial weight 245 
or the mice became sick and unable to feed. 246 
 247 
2.10 Therapeutic Model of TUBO Challenge 248 
 249 
To evaluate the anti-tumor efficacy of AE37 displaying phages and control λF7, 5×105 TUBO 250 
cells in 50 µL PBS buffer were injected in the right flank of 4-6 week old female BALB/c mice. 251 
Two weeks after tumor inoculation, 108 PFU of AE37 displaying phages, λ F7 or TN buffer (100 252 
µL/mouse) were injected subcutaneously (SC) three times at 2-week intervals. The TN buffer 253 
and λF7 were used as controls. Mice without any tumor considered as tumor-free at the end of 254 
the experiment. Again, mice were euthanized if the tumor volume was greater than 1000 mm3, or 255 
the body weight reached below 15% of initial mass or the mice became lethargic or sick or 256 
unable to feed. Mice were monitored every day and the tumor volume was measured and 257 
calculated as mentioned above. 258 
 259 
 260 
2.11 Statistical analysis 261 
 262 
Two-way analysis of variance (ANOVA) followed by Tukey’s post-test were performed to 263 
assess the significance of the differences among various formulations. Survival data expressed as 264 
survival probability was analyzed by log-rank test to compare survival curve between groups. 265 
Results with P < 0.05 were considered significant. All statistical analyses were performed using 266 
Graph Pad Prism 6 Software. * Means P. value < 0.05, ** means P. value < 0.01, *** means P. 267 
value < 0.001, **** means P. value < 0.0001. 268 
 269 
 270 
 271 
3. Results  272 
 273 
3.1 Endotoxin removal from phage lysates 274 
 275 
Triton X-114 was used for endotoxin removal. In order to maximize endotoxin elimination, the 276 
phage purification procedure was repeated three times. LAL results showed that samples 277 
contained < 12 EU/mL. This amount is considered an injectable grade of endotoxin level for 278 
animals [25]. 279 
 280 
3.2 Determination of CD8+ T-cells by flow cytometry 281 
 282 
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The percentage of CD8+ T cells within the CD8+lymphocyte population was significantly 283 
enhanced in mice injected with λF7 (gpD::AE37) compared to controls groups (P < 0.05) (Fig. 284 
1). 285 
 286 
3.3 Antigen-specific cytotoxicity by λF7 (gpD::AE37) 287 
Cytotoxicity assays provide an in vitro evaluation of the lytic activity of T cells against tumors 288 
[26]. The λF7 (gpD::AE37) phage was significantly effective in generating CTL response. The 289 
activity was established significantly at both various effector to target (E/T) ratio (at 2.5/1 and 290 
10/1) in comparison with the λF7 and TN buffer groups (P < 0.0001) and (P < 0.001). This 291 
response was antigen specific because the CTL response was not observed against CT26 tumor 292 
cells (rHER2/neu negative) (Fig. 2). 293 
3.4. IL-4 and IFN-γ production assays 294 
The sera of immunized mice (three animals per group) were collected 14 days after the last 295 
booster and assayed for IL-4 and IFN-γ by ELISA. Mice stimulated with λF7 (gpD::AE37) 296 
secreted higher levels of IL-4 (P < 0. 01) and IFN-γ compared to λF7 and buffer groups (Fig. 3).  297 
 298 
3.5 Prophylactic study 299 
 300 
108 PFU of AE37 displaying phages and λ F7 (100 µL/mouse) were used to vaccinate mice 301 
subcutaneously at two week intervals. Two weeks after the third vaccination all groups were 302 
challenged with 5 × 10 5 TUBO cells by injection on right flank and the mice were observed for 303 
any touchable tumor on the right flank. Tumor growth curve analysis indicated that the λF7 304 
(gpD::AE37) and λF7 groups were the most effective groups in terms of reducing the growth rate 305 
of the tumor ( P <0.0001) and (P <0.001) in comparison to TN buffer (Fig. 4.A). The 306 
prophylactic effects observed in mice model groups are summarized in Table 2 indicating 307 
median survival time (MST), time to reach end point (TTE) and tumor growth delay (% TGD) 308 
for each mice group. 309 
Survival analysis revealed that the λF7 (gpD::AE37) and λF7 group had significantly prolonged 310 
MST, TTE and % TGD compared to the TN buffer (P <0. 01) (Fig. 4.B).   311 
 312 
                       313 
3.6 Therapeutic study 314 
 315 
In the therapeutic evaluation study, 5 ×10 5
 
TUBO
 
cells per mice were subcutaneously injected in 316 
the right flank of experimental and control animals. After observation of a palpable tumor, 317 
vaccination was started for three times with two week intervals. Weights of mice and sizes of 318 
tumors were measured regularly until mice became lethargic or size of tumors was reached up to 319 
1000 mm3. The candidate vaccine formula λF7 (gpD::AE37) decreased the size of tumor 320 
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significantly (P < 0.001) and λF7 group (P < 0.05) in comparison with TN buffer (Fig. 5. A). In 321 
the λF7 (gpD::AE37) vaccination group an increased survival time was observed (P < 0.05) 322 
which in comparison with λF7and TN buffer groups was statistically significant (Fig. 5. B). The 323 
therapeutic effects observed in mice model groups are summarized in Table3 indicating median 324 
survival time (MST), time to reach end point (TTE) and tumor growth delay (% TGD) for each 325 
mice group. 326 
 327 
 328 
 329 
 330 
4. Discussion  331 
 332 
The goal of our study was to investigate the immunogenicity and anti-tumor activity of the 333 
chimeric λ phage nanoparticles displaying immunogenic AE37 peptide, λF7 (gpD::AE37) in a 334 
TUBO tumor model of BALB/c mice. Cancer peptide vaccines, based on tumor-associated 335 
antigens (TAA), can induce cellular and humoral immune response against the tumor or they 336 
may cause an enhancement of an endogenous antitumor immunity pre-existing in the host [27]. 337 
HER2/neu is a receptor belonging to the epidermal growth factor receptor family the 338 
overexpression of which has been observed in 18–20% of human breast cancers and linked to a 339 
poor prognosis [28]. 340 
In the last few years, different HER2/neu-derived epitopes have been targeted simultaneously, 341 
leading to a heightened response. AE37 is a hybrid peptide which is composed of the covalent 342 
linkage of the Ii-Key peptide (LRMK), to the HER2 derived AE36 amino-terminus [29]. Some 343 
studies have shown that Ii-Key hybrid peptide, enhanced the presentation of antigenic peptides 344 
by APCs to T cells, stimulated peptide-specific CD4+ T cells more impressive than native 345 
peptides and provided potent helper effect to HER2-specific CD8+ T cells in animal models [30]. 346 
The AE37 peptide vaccine, with the LRMK sequence, can facilitate MHC class II molecule 347 
loading and increased potency compared with unmodified class II epitopes [31]. It has been 348 
reported that AE37 is a multi epitope vaccine. It is capable of inducing both specific CD4+ and 349 
CD8+ T cells in vaccinated cancer patients [32]. It has been hypothesized that AE37-induced T-350 
helper cells may engage dendritic cells at tumor site, thereby cross-presenting antigens from 351 
apoptotic tumor cells and inducing epitope spreading [33] . Immunization with a HER-2 helper 352 
peptide could elicit tumor specific CTLs via cross-presentation [7]. The induced immune 353 
responses might be directed against the targeted epitope as well as against a broad range of tumor 354 
associated epitopes [9, 10]. Moreover, the AE37 peptide stimulates CD4+ Th cells rendering 355 
them capable of inducing immunologic memory and persistent stimulation of CTLs. AE37 356 
induced T cells, secreting mainly Th1 cytokines, may activate dendritic cells present in tumor 357 
microenvironment. Under these conditions the cross-presentation phenomenon could be 358 
enhanced resulting in an epitope spreading [11]. 359 
  360 
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Furthermore, phase II trial investigating AE37 + GM-CSF based vaccines have shown its 361 
effectiveness in stimulating peptide-specific immunity, especially in CD8+ T cell stimulation 362 
with anti-tumor activity in breast cancer patients but these patients experienced grade 1 local and 363 
systemic toxicity due to the GM-CSF. The most common systemic toxicities have been 364 
influenza-like symptoms, fatigue and bone pain [34].   365 
A nanoliposomal AE36 vaccine with CpG adjuvant has shown a considerable effect in 366 
prophylactic and therapeutic studies in mice [35]. Designing suitable delivery systems based on 367 
immune-stimulating complexes that have a long circulation time and their tendency to be taken 368 
up more efficiently by APCs to induce CTL response can therefore provide considerable 369 
improvement in vaccination [36]. Due to the several great beneficial features including large 370 
multivalent display, ease of manufacture, excellent safety profile and intrinsic adjuvant activity 371 
the phage display technique is on the focus for a rapid development for anticancer vaccine 372 
development and cancer vaccine delivery [37].  373 
The lambda phage vector is about 1000 times more efficient than a plasmid vector to transform a 374 
target peptide molecule. It can be converted to a plasmid for the production of foreign peptides 375 
and proteins. Moreover, the ease of plaque screening and the efficiency of infection with lambda 376 
is evident [38]. In a recent study, we have shown that λF7 (gpD::E75) particles displaying the 377 
E75 peptide (another HER2 derived molecule), can stimulate specific CD8+ T cells in vitro [1]. 378 
Lambda and T7 phage display  systems have shown to be able to elicit a B cell response in 379 
cancer cells [39]. Recombinant λ phage nanoparticles carrying HBsAg (hepatitis B surface 380 
antigen) stimulated specific antibodies production in rabbits and mice [40]. The peptide 381 
inoculant λ gfp10-GFP-TAT and hybrid DNA could induce the greatest amplitude of an IFN-γ 382 
production in CD1 mice [41]. Phages displaying the melanoma antigen (MAGE161–169) produced 383 
significant CTL immune responses against a tumor-associated antigen epitope leading to 384 
therapeutic and protective effects in a C57BL/6J mice model [42].  385 
In this study, we employed λF7 phage particles displaying the AE37 peptide (AE36, HER2776-790 386 
linked to LRMK peptide) on λF7 (gpD::AE37). The immunogenicity and antitumor potential of 387 
the λF7 (gpD::AE37) was investigated using in vivo and in vitro assays. BALB/c mice were 388 
immunized subcutaneously three times with endotoxin-free λF7 (gpD::AE37) phage 389 
nanoparticles. Our data demonstrated that the λ phage could act as an endogenous adjuvant. The 390 
bacterial pathogen-associated molecular patterns (PAMPs) probably act as an endogenous 391 
adjuvant. The observed immunogenicity of the control phage in the prophylactic and therapeutic 392 
settings has been reported consistently in our other projects including one of our recently 393 
published studies [43]. The effects in the prophylactic setting may even be higher due to longer 394 
exposure time. Higher prophylactic (compared to therapeutic) effects of bacteriophages has been 395 
reported in other settings [44]. It has also been reported by many investigators that phage 396 
particles are inherently immunogenic and can serve as effective natural adjuvants.  This is why 397 
phage display vaccines may be effective without adjuvants that are frequently used along with 398 
recombinant proteins and synthetic peptides to improve immune response [45]. This inherent 399 
immunogenicity is considered a great advantage for the phage vaccines in addition to their many 400 
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other advantages including their high multivalent display potential, safety profile, and ease of 401 
manufacturing and construction [46, 47]. Therefore, the observed immunogenicity by the empty 402 
phage particles are expected to be seen.  The flow cytometry assays showed that mice 403 
immunized with λF7 (gpD::AE37) nanoparticles could induce a significant CD8+ T-cell response 404 
compared to control groups. In addition, cytotoxicity assays showed that mice immunized with 405 
λF7 (gpD::AE37) nanoparticles could induce a higher CTL activity compared to λF7 and buffer 406 
groups indicating the crucial role of the repetitive display of AE37 peptide on the surface of λ 407 
nanoparticles. In vivo studies demonstrated that λF7 (gpD::AE37) nanoparticles decreased tumor 408 
growth and possessed superior anti-tumor activity in both prophylactic and therapeutic assays. 409 
Also, it was able to increase the survival time of the TUBO cell line (HER2-over expressing) 410 
tumor bearing mice. We also report that λF7 successfully induced tumor-specific CTL activity 411 
immune responses in comparison to the TN buffer. The control λF7 did not show in vitro 412 
induction of CD8+ T-cell and CTL activity. 413 
 In summary, the results of this study demonstrates that vaccination with lambda phage 414 
nanoparticles expressing AE37 peptide, λF7 (gpD::AE37) led to the induction of specific CTL 415 
immune response in vitro and in vivo. Moreover, the delivery of AE37 peptide by λ 416 
bacteriophage has significantly enhanced the anti-tumor immune function compared to the 417 
control groups. In fact, we think that there is a potential for the λF7 (gpD::AE37) phage 418 
nanoparticles for antitumor vaccine development as the phage construct was found to elicit 419 
inhibitory effects on the TUBO tumor (HER2/neu overexpressing implantable tumor) and 420 
therefore we think that our data merits further investigation. Further studies into the exploitation 421 
of the vaccine candidate is underway. 422 
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Table 1. Bacterial strains, plasmids and phages used in this study 
Designation Genotype Source/Reference 
Bacterial strains 
BB4                                  supF58 supE44 hsdR514 galK2 galT22 trpR55 metB1 tonA 
DE(lac) U169   
Agilent Technologies, Inc 
W3101                              F−, galT22, λ−, IN(rrnD-rrnE)1, rph-1   CGSC #4467, Bachmann et al 
(Bachmann, 1972) 
W3101 SupE                    F−, galT22, λ−, IN(rrnD-rrnE)1, rph-1 crcA280::Tn10, 
glnV44(AS) 
Nicastro et al (Nicastro, et al., 2013) 
Phages 
λF7                                         λDam15imm21CIts   Mikawa et al (Mikawa, et al., 1996) 
λF7 (gpD::AE37)      λDam15imm21CIts   This study 
Plasmids 
pPL451gpD                   pM-cI857-pL-cI857-pL- D-tL      Sokolenko et al (Sokolenko, et al., 
2012) 
pGPD::AE37                    pM-cI857-pL-cI857-pL- D::E37-tL                                                       This study                                    
 
 
 
 
Table 2: Protective efficacy data in TUBO tumor mice model (n = 7)  
Formulation MSTa (Day) TTEb (Day) ± SD TGDc (%) 
λF7 (gpD::AE37) 98 99 ± 20 62 
λF7 90 92 ± 12 51 
TN buffer 67 61 ± 33 - 
a     Median survival time 
b
   Time to reach end point 
c
   Tumor growth delay 
 
 
 
Table 3: Therapeutic efficacy data of the vaccine in TUBO tumor mice model (n = 7). 
Formulation MSTa (Day) TTEb (Day) ± SD TGDc (%) 
λF7(gpD::AE37) 60 64 ± 1 115 
λF7 43 52 ± 9 70 
TN buffer 44 30 ± 6 - 
a     Median survival time 
b
   Time to reach end point 
c
   Tumor growth delay 
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Fig. 1. Flow cytometry assay with splenocytes of immunized mice. Fourteen days after the last 
immunization, splenocytes were isolated and stimulated in vitro with PMA/I for 4 h and stained 
with a surface CD8. Percentage of CD8+ T cells significantly increased in λF7 (gpD::E37) group 
compared to λF7 and TN buffer groups *(P < 0.05). The results represent mean ± SEM (n = 3). 
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Fig. 2. Antigen - Specific CTL response induced by various formulations at two different ratios of 
effector to target cells (E/T) was assessed using an in vitro CTL activity assay. Splenocytes from 
the mice (from three mice in each group) were incubated with Calcein AM-loaded rHER2/neu-
expressing TUBO tumor cells and rHER2/neu-expressing negative CT26 cells (as rHER2/neu 
negative control). The mice immunized with λF7 (gpD::E37) showed significantly higher CTL 
activity compared to λF7 and buffer groups at E/T ratios. ***P <0. 001 and ****P <0.0001. The 
results represent mean ± SEM (n = 3).  
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Fig. 3. Secretion of IL-4 and IFN-γ cytokines induced by phages expressing AE37 peptide. 
BALB/c mice were immunized with λF7 (gpD::AE37) every 2 weeks for three times. Blood 
samples were collected 14 days after the last booster and the concentration of IL-4 and IFN-γ 
cytokines was determined using ELISA. Mice immunized with λF7 (gpD::AE37) showed higher 
levels of IL-4 and IFN-γ cytokines compared to λF7 and buffer groups. Data represent mean ± 
SD (n = 3). **(P < 0. 01) 
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Fig. 4. Protective effects of vaccination with λF7 (gpD::AE37) phage in BALB/c mice against a 
TUBO tumor model. Two weeks after the last booster, seven mice in each group were challenged 
subcutaneously on right flank with 5 ×105 TUBO cells. Mice were observed for tumor growth (A) 
and survival (B). Tumor size was calculated twice per week, based on the three dimensions. The 
survival of mice was followed for 100 days. The data indicate mean ± SEM (n = 7). **P < 0.01, 
*** P < 0.001 and **** P < 0.0001; denotes significant difference from the TN buffer and control 
groups. 
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Fig. 5. Therapeutic effects of λF7 (gpD::AE37) phage nanoparticles against the HER2 expressing 
TUBO tumor of BALB/c mice. Two weeks after injection of 5 ×105 TUBO cells (seven mice in 
each group) the mice were administrated with the samples for three times at two week intervals. 
After the first injection, the mice were challenged and tumor size was calculated based on the three 
dimensions. (A) Tumor growth was measured twice per week. (B) Mice survival was followed for 
74 days. The data indicate mean ± SEM (n = 7).  *P < 0.05 denotes significant effects compared 
to the TN buffer group. 
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• Bacteriophage λ displaying the HER2/neu derived peptide AE37 
 
• Immunological studies on TUBO cancer cell line and mice bearing HER2+ 
breast cancer. 
 
• Prophylactic and therapeutic studies on mice bearing HER2+ breast cancer. 
